Related Announcements

RFA-DK-21-020 - Elucidating the Heterogeneity of Impaired Awareness of Hypoglycemia in Type 1 Diabetes (T1D) Clinical Centers (U01 Clinical Trial Required)

Issued by

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Purpose

This Notice is to inform the applicant community of a decrease in funds available for Funding Opportunity Announcement (FOA) RFA-DK-21-020, "Elucidating the heterogeneity of impaired awareness of hypoglycemia in Type 1 Diabetes (T1D) Clinical Centers (U01 Clinical Trial Required)". The amount committed for FY 2022 ($4.72 million) has not changed. However, the amounts allotted for the remaining years of the projects have decreased.

Therefore, Section II., the Award Information, Award Budget section of the FOA has been updated to more accurately reflect the funds available as shown below:

Currently Reads:

Section II. Award Information

Award Budget

Application budgets need to reflect the actual needs of the proposed project. Application awards are limited to $250,000 Direct Costs in grant year 1; $500,000 Direct Costs in grant year 2; $600,000 Direct Costs in grant year 3, $600,000 Direct Costs in grant year 4 and $500,000 in Direct costs in grant year 5.

Modified to Read (changes shown in bold italics)

Section II. Award Information

Award Budget

Application budgets need to reflect the actual needs of the proposed project. Application awards are limited to $250,000 Direct Costs in grant year 1; $470,000 Direct Costs in grant year 2; $540,000 Direct Costs in grant year 3, $540,000 Direct Costs in grant year 4 and $470,000 in Direct costs in grant year 5.
 

All other aspects of this Funding Opportunity Announcement remain the same.

Inquiries

Please direct all inquiries to:

Karen Teff, Ph.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-594-8803
Email: [email protected]